IGM Biosciences, Inc. financial data

Symbol
IGMS on Nasdaq
Industry
Pharmaceutical Preparations
Location
325 E Middlefield Road, Mountain View, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Palingen, Inc. (to 7/16/2010)
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 707 % -23.5%
Debt-to-equity 155 % +80.1%
Return On Equity -155 % -69.4%
Return On Assets -61 % -23.7%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 132M USD -39.7%
Weighted Average Number of Shares Outstanding, Basic 60.7M shares +1.81%
Weighted Average Number of Shares Outstanding, Diluted 60.7M shares +1.81%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 186M USD -9.81%
General and Administrative Expense 51.5M USD +2.83%
Operating Income (Loss) -235M USD +7.81%
Nonoperating Income (Expense) 15.1M USD -9.72%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -220M USD +7.68%
Income Tax Expense (Benefit) 242K USD -44.5%
Net Income (Loss) Attributable to Parent -220M USD +7.74%
Earnings Per Share, Basic -3.54 USD/shares +28.3%
Earnings Per Share, Diluted -3.54 USD/shares +28.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.9M USD -75.5%
Marketable Securities, Current 236M USD -19.1%
Assets, Current 230M USD -42.4%
Property, Plant and Equipment, Net 34.7M USD -6.04%
Operating Lease, Right-of-Use Asset 39.1M USD +5.38%
Other Assets, Noncurrent 1.14M USD -42.6%
Assets 305M USD -35.8%
Accounts Payable, Current 3.55M USD -9.41%
Accrued Liabilities, Current 31.1M USD +11.2%
Liabilities, Current 44M USD +2.33%
Operating Lease, Liability, Noncurrent 39.2M USD +11.9%
Other Liabilities, Noncurrent 554K USD
Liabilities 226M USD +2.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 421K USD
Retained Earnings (Accumulated Deficit) -980M USD -28.9%
Stockholders' Equity Attributable to Parent 78.9M USD -68.9%
Liabilities and Equity 305M USD -35.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -42.4M USD +16.8%
Net Cash Provided by (Used in) Financing Activities 152K USD +103%
Net Cash Provided by (Used in) Investing Activities 8.65M USD -87.6%
Common Stock, Shares Authorized 120M shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -33.6M USD -278%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.1M USD -75.4%
Deferred Tax Assets, Valuation Allowance 267M USD +41.4%
Deferred Tax Assets, Gross 280M USD +39.4%
Operating Lease, Liability 40.5M USD -1.62%
Depreciation 2.18M USD +30.8%
Payments to Acquire Property, Plant, and Equipment 2.48M USD -36.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -219M USD +7.84%
Lessee, Operating Lease, Liability, to be Paid 55.2M USD -10.4%
Property, Plant and Equipment, Gross 58.8M USD +28.4%
Operating Lease, Liability, Current 6.7M USD +7.88%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.1M USD -17.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 7.89M USD +14.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.3M USD -18.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.21M USD +1.72%
Deferred Tax Assets, Operating Loss Carryforwards 73.4M USD -8.78%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 10.6M USD +52.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.38M USD +2.74%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%